Amedisys Reports Second Quarter 2021 Financial Results, Closing of Contessa Acquisition, Expansion of Credit Facility and Authorization of New $100 Million Share Repurchase Program

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to Amedisys Reports Second Quarter 2021 Financial Results, Closing of Contessa Acquisition, Expansion of Credit Facility and Authorization of New $100 Million Share Repurchase Program

Amedisys (AMED) Tops Q2 EPS by 2c

August 4, 2021 4:07 PM EDT

Amedisys (NASDAQ: AMED) reported Q2 EPS of $1.69, $0.02 better than the analyst estimate of $1.67. Revenue for the quarter came in at $564.2 million versus the consensus estimate of $566.19 million.

GUIDANCE:

Amedisys sees Q3 2021 EPS of $6.37-$6.49, versus the consensus of $6.96. Amedisys sees Q3... More